Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Phys Rev Lett ; 123(5): 052501, 2019 Aug 02.
Artículo en Inglés | MEDLINE | ID: mdl-31491316

RESUMEN

Differences between ν_{e} and ν_{µ} quasielastic cross sections are essential in neutrino oscillation analyses and CP violation searches for experiments such as DUNE and T2HK. The ratio of these is however poorly known experimentally and for certain kinematic regions theoretical models give contradictory answers. We use two independent mean-field based models to investigate this ratio using ^{40}Ar and ^{12}C targets. We demonstrate that a proper treatment of the final nucleon's wave function confirms the dominance of ν_{µ} over ν_{e} induced cross sections at forward lepton scattering.

2.
Curr Med Chem ; 18(11): 1599-612, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21428886

RESUMEN

Treatment of metastatic colorectal cancer (mCRC) has progressed significantly over the last years, particularly with the introduction of targeted therapies. Two groups of agents targeting either the epidermal growth factor receptor (EGFR) or the vascular endothelial growth factor (VEGF) have been integrated into clinical practice. Currently available agents with established role include the anti-EGFR monoclonal antibodies (mAbs) cetuximab / panitumumab and the anti-VEGF mAb bevacizumab. This review presents an update on the clinical studies evaluating the role of anti-EGFR and anti-VEGF agents in mCRC. Moreover, we provide current data regarding the mechanism of action and pathways mediating resistance to these agents. In addition, we present recent data with respect to biomarkers and we discuss future therapeutic strategies.


Asunto(s)
Neoplasias Colorrectales/tratamiento farmacológico , Terapia Molecular Dirigida/métodos , Antineoplásicos/uso terapéutico , Neoplasias Colorrectales/patología , Receptores ErbB/antagonistas & inhibidores , Predicción , Humanos , Terapia Molecular Dirigida/tendencias , Metástasis de la Neoplasia/tratamiento farmacológico , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA